Gate App Options Now Live! Test and Win Big
📅 Event Period: September 30, 2025 – October 17, 2025
- Submit valid feedback to receive 10–100 USDT.
- Complete at least 10,000 USDT in cumulative options trading volume to participate.
👉 Register now :https://www.gate.com/campaigns/2063
Details: https://www.gate.com/zh-tw/announcements/article/47455
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.